Table 4.
Multivariable‐Adjusted HRs for Higher Levels of 21‐Gene Recurrence Scores for Early‐Stage, Hormone Receptor–Positive Invasive Breast Cancer Among Women With DCIS in SEER, 1990‐2015
| Person‐y | Recurrence Scores | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| <18 | ≥18 | <26 | ≥26 | ||||||
| Cases, No. | HRa (95% CI) | Cases, No. | HRa (95% CI) | Cases, No. | HRa (95% CI) | Cases, No. | HRa (95% CI) | ||
| White | 1,018,475 | 421 | 1.00 | 421 | 1.00 | 602 | 1.00 | 240 | 1.00 |
| Black | 129,931 | 58 | 1.11 (0.84‐1.46) | 68 | 1.29 (1.00‐1.67) | 84 | 1.13 (0.90‐1.42) | 42 | 1.38 (1.00‐1.92) |
| Asian | 128,657 | 77 | 1.37 (1.07‐1.75) | 57 | 0.97 (0.73‐1.28) | 97 | 1.19 (0.96‐1.48) | 37 | 1.11 (0.78‐1.57) |
| Hispanic | 102,614 | 50 | 1.17 (0.87‐1.57) | 32 | 0.71 (0.50‐1.02) | 64 | 1.03 (0.80‐1.34) | 18 | 0.71 (0.44‐1.14) |
| P heterogeneity = .046 | P heterogeneity = .057 | ||||||||
Abbreviations: CI, confidence interval; DCIS, ductal carcinoma in situ; HR, hazard ratio; SEER, Surveillance, Epidemiology, and End Results.
Hazard ratios were adjusted for the following: age (20‐39, 40‐49, 50‐59, 60‐69, or ≥70 years) and year of the primary DCIS diagnosis (1990‐1999, 2000‐2009, or 2010‐2015); treatment for primary DCIS (no surgical treatment, breast‐conserving surgery alone, breast‐conserving surgery followed by radiation therapy, mastectomy, or unknown); and histopathological features of primary DCIS, including the tumor size (<2 cm, 2‐5 cm, ≥5 cm, or unknown), grade (well differentiated, moderately differentiated, poorly differentiated, or unknown), histology (comedo, papillary, cribriform, solid, or not otherwise specified), and hormone receptor expression (positive, negative, or unknown).